Delirium in older hospital patients is common, often missed, and often preventable
A landmark trial cut delirium from 15.0% to 9.9% by addressing six ordinary risk factors together. Drugs, including antipsychotics, have not shown the same clear preventive benefit.
| Group | Value (%) |
|---|---|
| Multicomponent intervention | 9.9 |
| Usual care | 15 |
Delirium — an acute, fluctuating disturbance of attention and awareness — is one of the most common serious complications of hospital admission in older people, and one of the most frequently overlooked. It is also, to an unusual degree, preventable. The strongest evidence is not for a drug but for a bundle of basic care: a trial that addressed six ordinary risk factors together cut new delirium from 15.0% of patients to 9.9% [s1]. Drugs, by contrast, have not shown a clear preventive effect [s2].
Nothing here is a treatment instruction; it describes what the evidence shows about preventing a hospital complication. A patient who becomes suddenly confused in hospital needs urgent clinical assessment, because delirium can be the first sign of a treatable underlying illness.
Why it is missed
Delirium is distressing and carries serious consequences — longer stays, functional decline, and higher risk of long-term cognitive impairment and death. Yet it is routinely under-recognised, particularly its hypoactive form, which presents not as agitation but as lethargy, withdrawal and reduced responsiveness — easily mistaken for tiredness or low mood, or dismissed as the patient being "a bit vague." Older patients and those with existing dementia are most at risk, and are exactly the group whose baseline makes the change hardest to notice without deliberate screening.
What the landmark trial did
The Hospital Elder Life Program trial studied 852 patients aged 70 or older admitted to a general-medicine service [s1]. Rather than treat delirium once it appeared, it targeted six risk factors with standardised protocols: cognitive impairment, sleep deprivation, immobility, visual impairment, hearing impairment and dehydration [s1]. In practice that meant reorientation and cognitive activities, non-drug sleep protocols, early mobilisation, vision and hearing aids, and attention to fluids.
The results were clear. Delirium developed in 9.9% of the intervention group against 15.0% under usual care (matched odds ratio 0.60, 95% confidence interval 0.39 to 0.92) [s1]. The total number of days with delirium (105 versus 161) and the number of episodes (62 versus 90) were both significantly lower [s1]. The programme was also deliverable: overall adherence to the protocols was 87%, and it produced measurable side benefits — improved cognition among patients who arrived already cognitively impaired, and a lower rate of sleeping-pill use across the whole group [s1]. Two limits are worth stating plainly: the programme reduced how often delirium started, but once it occurred, its severity and recurrence rates were no different [s1]. Prevention, not rescue, is where the benefit lies.
Why drugs are not the answer
Because delirium sometimes involves agitation, sedating and antipsychotic drugs are often reached for. The evidence does not support them as prevention. A Cochrane review of 39 trials involving 16,082 patients concluded there is strong evidence for multicomponent, non-pharmacological interventions — and no clear evidence that antipsychotic medications as a group prevent delirium (risk ratio 0.73, 95% CI 0.33 to 1.59) [s2]. Cholinesterase inhibitors showed no clear benefit, and melatonin's effect was uncertain (RR 0.41, 95% CI 0.09 to 1.89) [s2]. The one anaesthetic signal was procedural: monitoring depth of anaesthesia to avoid over-sedation reduced postoperative delirium (RR 0.71, 95% CI 0.60 to 0.85) [s2] — again, less drug rather than more.
How to read this
The message is consistent across two decades of evidence. What prevents delirium is unglamorous, systematic attention to the basics — keeping people oriented, mobile, hydrated, sleeping, and able to see and hear. Several of those overlap with the wider geriatric evidence: correcting sensory loss, which is itself linked to cognition, and protecting the sleep that changes with age but should not be knocked out with sedatives. Where drugs come in, the network meta-analysis of delirium-prevention agents found almost nothing that reliably changed the outcomes that matter.
What to watch
The gap now is implementation, not discovery: multicomponent programmes work but require staff, coordination and consistency that stretched wards struggle to sustain. For families, the practical value is knowing that sudden confusion in an older hospital patient is not to be shrugged off as "just the hospital," but flagged — early recognition is part of what turns a preventable episode into a treated one.
Sources
- A multicomponent intervention to prevent delirium in hospitalized older patients — New England Journal of Medicine , March 1, 1999
- Interventions for preventing delirium in hospitalised non-ICU patients — Cochrane Database of Systematic Reviews , March 11, 2016
More on
Treating failing sight and hearing may lower dementia risk — the evidence is uneven
Cataract surgery was tied to 29% lower dementia risk in a strong cohort. But the largest hearing-aid trial found no overall effect on cognition. The signal is real; the proof that fixing senses prevents dementia is not.
The largest trial of hearing aids and cognitive decline found no overall effect
ACHIEVE randomised 977 older adults and measured three-year cognitive change. The difference between hearing aids and health education was 0.002 SD units, p=0.96. One subgroup result is doing a lot of work.
Supporting dementia caregivers can delay a nursing home and protect the carer's mind
Structured counselling for a spouse delayed a patient's nursing-home admission by an estimated 557 days. Other trials cut carer depression sharply, though the effect on institutionalisation is less consistent.
A statin cut heart attacks in healthy over-70s. Independent years did not follow.
STAREE randomised 9,971 Australians aged 70 and over to atorvastatin or placebo. Cardiovascular events fell by 30%. Death, dementia and persistent disability, taken together, did not move.